Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study

被引：2

作者：

Furubayashi, Nobuki ^{[1
]}

Morokuma, Futoshi ^{[2
]}

Tomoda, Toshihisa ^{[3
]}

Hori, Yoshifumi ^{[4
]}

Negishi, Takahito ^{[1
]}

Miura, Akihiro ^{[1
]}

Komori, Hiroki ^{[1
]}

Kuroiwa, Kentaro ^{[4
]}

Nakamura, Motonobu ^{[1
]}

机构：

[1] Natl Hosp Org Kyushu Canc Ctr, Dept Urol, Fukuoka, Japan

[2] Saga Ken Med Ctr Koseikan, Dept Urol, Saga, Japan

[3] Oita Prefectural Hosp, Dept Urol, Oita, Japan

[4] Miyazaki Prefectural Miyazaki Hosp, Dept Urol, Miyazaki, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 03期

关键词：

chemotherapy pembrolizumab; real -world clinical practice; Advanced urothelial carcinoma; platinum-based; IMMUNE CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; GEMCITABINE; CARBOPLATIN; CISPLATIN; CANCER; TUMORS; CELLS;

D O I：

10.21873/anticanres.15631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear. Patients and Methods: Thirty-four patients who received pembrolizumab as second-line treatment after firstline platinum-based chemotherapy were retrospectively evaluated. Results: According to overall survival (OS) from pembrolizumab, there was a significant difference between <= 4 and 0.001), but not between <= 6 and 6 cycles (18.6 and 27.3 months, p=0.276). Conclusion: The optimal timing of switching from platinum-base chemotherapy to pembrolizumab in advanced UC is around six cycles.

引用

页码：1571 / 1577

页数：7

共 50 条

[1] Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Massari, Francesco
Santoni, Matteo
Takeshita, Hideki
Okada, Yohei
Tapia, Jose Carlos
Basso, Umberto
Maruzzo, Marco
Scagliarini, Sarah
Buettner, Thomas
Fornarini, Giuseppe
Myint, Zin W.
Galli, Luca
Souza, Vinicius Carrera
Pichler, Renate
De Giorgi, Ugo
Gandur, Nathalia
Lam, Elaine T.
Gilbert, Danielle
Popovic, Lazar
Grande, Enrique
Mammone, Giulia
Berardi, Rossana
Crabb, Simon J.
Kemp, Robert
Molina-Cerrillo, Javier
Freitas, Marcelo
Luz, Murilo
Iacovelli, Roberto
Calabro, Fabio
Tural, Deniz
Atzori, Francesco
Kueronya, Zsofia
Chiari, Rita
Campos, Saul
Caffo, Orazio
Fay, Andre P.
Kucharz, Jakub
Zucali, Paolo Andrea
Rinck, Jose Augusto
Zeppellini, Annalisa
Bastos, Diogo Assed
Aurilio, Gaetano
Mota, Augusto
Trindade, Karine
Ortega, Cinzia
Sade, Juan Pablo
Rizzo, Mimma
Fiala, Ondrej
Vau, Nuno
Giannatempo, Patrizia
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (06)
[2] Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study
Rose, Kyle M.
Pham, Rachel
Zacharias, Niki M.
Ionescu, Filip
Paravathaneni, Mahati
Marchetti, Kathryn A.
Sanchez, Darren
Mustasam, Arfa
Sandstrom, Reagan
Vikram, Raghu
Dhillon, Jasreman
Rao, Priya
Schneider, Amy
Pagliaro, Lance
Alifrangis, Constantine
Albersen, Maarten
Roussel, Eduard
Master, Viraj A.
Nazha, Bassel
Hernandez, Cindy
Moses, Kelvin A.
Protzel, Chris
Montgomery, Jeffrey
Angel, Martin
Tobias-Machado, Marcos
Spiess, Philippe E.
Pettaway, Curtis A.
Chahoud, Jad
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (06): : 966 - 973
[3] Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
Furubayashi, Nobuki
Negishi, Takahito
Takamatsu, Dai
Ieiri, Kosuke
Inoue, Tomohiro
Tsukino, Keiji
Nakamura, Motonobu
ONCOLOGY LETTERS, 2020, 19 (04) : 2943 - 2949
[4] Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
Uchida, Hideaki
Obinata, Daisuke
Takada, Shogo
Yoshizawa, Tsuyoshi
Mochida, Junichi
Yamaguchi, Kenya
Takahashi, Satoru
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (05)
[5] A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma
Yamamoto, Shoma
Kato, Minoru
Takeyama, Yuji
Yukimatsu, Nao
Hirayama, Yukiyoshi
Otoshi, Taiyo
Yamasaki, Takeshi
Kuratsukuri, Katsuyuki
Uchida, Junji
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (05) : 194.e7 - 194.e14
[6] Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma
Yumioka, Tetsuya
Honda, Masashi
Shimizu, Ryutaro
Teraoka, Shogo
Yamaguchi, Noriya
Kawamoto, Bunya
Iwamoto, Hideto
Morizane, Shuichi
Hikita, Katsuya
Takenaka, Atsushi
ANTICANCER RESEARCH, 2021, 41 (11) : 5767 - 5773
[7] Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
Furubayashi, Nobuki
Negishi, Takahito
Sakamoto, Naotaka
Tamura, Shingo
Morokuma, Futoshi
Song, Yoohyun
Hori, Yoshifumi
Tomoda, Toshihisa
Seki, Narihito
Kuroiwa, Kentaro
Nakamura, Motonobu
IN VIVO, 2021, 35 (05): : 2869 - 2874
[8] Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
Furubayashi, Nobuki
Negishi, Takahito
Miura, Akihiro
Nakamura, Nobutaka
Nakamura, Motonobu
RESEARCH AND REPORTS IN UROLOGY, 2020, 12 : 455 - 461
[9] TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica, Veronica
Tassinari, Elisa
Santoni, Matteo
Marchese, Paola Valeria
Giunchi, Francesca
Maloberti, Thais
Tateo, Valentina
Ricci, Costantino
Rosellini, Matteo
Marchetti, Andrea
Fiorentino, Michelangelo
De Biase, Dario
Massari, Francesco
PATHOLOGY RESEARCH AND PRACTICE, 2024, 253
[10] Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
Shindo, Tetsuya
Hashimoto, Kohei
Takahashi, Atsushi
Miyamoto, Shintaro
Kunishima, Yasuharu
Sato, Shunsuke
Fukuta, Fumimasa
Hiyama, Yoshiki
Takayanagi, Akio
Kato, Ryuichi
Wanifuchi, Atsushi
Ueki, Yohei
Okada, Manabu
Adachi, Hideki
Kobayashi, Ko
Tanaka, Toshiaki
Masumori, Naoya
ANTICANCER RESEARCH, 2024, 44 (03) : 1271 - 1279

← 1 2 3 4 5 →